Certolizumab pegol
From Wikipedia, the free encyclopedia
 |
The introduction to this article provides insufficient context for those unfamiliar with the subject. Please help improve the article with a good introductory style. |
|
Certolizumab pegol?
|
|
| Therapeutic monoclonal antibody | |
| Source | human |
| Target | ? |
| Identifiers | |
| CAS number | ? |
| ATC code | ? |
| PubChem | ? |
| Chemical data | |
| Formula | ? |
| Mol. mass | ? |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
B(US) |
| Legal status | |
| Routes | Subcutaneous |
Certolizumab pegol (CDP870) (tradename Cimzia) is a PEGylated Fab' fragment of a humanized TNF inhibitor monoclonal antibody.
It is the subject of phase III clinical trials in both Crohn's disease[1] and rheumatoid arthritis. [2]
Positive results have been demonstrated in two phase III trials (PRECiSE 1 and 2) of certolizumab pegol vs placebo in moderate to severe active Crohn's disease.[citation needed] In addition, data from both trials suggest it is well-tolerated. As yet its efficacy has not been directly compared to other anti-TNF-alpha agents.[citation needed]
Preliminary results of the RAPID 1 &a 2 phase III studies were also reportedly positive.[3][4]
[edit] Legal status
On April 22, 2008, the United States Food and Drug Administration approved the drug for use in the United States on for the treatment of Crohn's disease in people who did not respond sufficiently or adequately to standard therapy.[5][6]
[edit] References
- ^ Sandborn WJ, Feagan BG, Stoinov S, et al (2007). "Certolizumab pegol for the treatment of Crohn's disease". N. Engl. J. Med. 357 (3): 228–38. doi:. PMID 17634458.
- ^ Kaushik VV, Moots RJ (2005). "CDP-870 (certolizumab) in rheumatoid arthritis". Expert opinion on biological therapy 5 (4): 601–6. doi:. PMID 15934837.
- ^ Keystone E, Mason D, Combe B. The anti-TNF certolizumab pegol in combination with methotrexate is significantly more effective than methotrexate alone in the treatment of patients with active rheumatoid arthritis: preliminary results from the RAPID 1 study. Ann Rheum Dis 2007;66(Suppl II):55 Presented at: EULAR 2007 Meeting; June 13-16, 2007; Barcelona, Spain. Abstract OP0016
- ^ Denise Mann Kleinman, "Certolizumab, First PEGylated TNF-Blocker, May Surpass Older Drugs in Efficacy, Safety", Muskuloskeletal Report June 16, 2007
- ^ UCB press release - Cimzia® Approved in the US for the Treatment of Moderate to Severe Crohn's Disease. Retrieved April 22, 2008.
- ^ Waknine, Yael (May 1, 2008). FDA Approvals: Patanase, Actonel, Cimzia. Medscape. Retrieved on 2008-05-01.
[edit] External links
|
|||||||||||||||||||||||
